Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Andrea M PeschNicole H HirshBenjamin C ChandlerAnna R MichmerhuizenCassandra L RitterMarlie P AndrosiglioKari Wilder-RomansMeilan LiuChristina L GerschJosé M LariosLori J PierceJames M RaeCorey W SpeersPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These studies provide preclinical rationale to test CDK4/6i and radiotherapy in women with locally advanced ER+ breast cancer at high risk for locoregional recurrence.